New Enterprise Associates, Inc. (NEA), a global venture capital firm, appointed Ross A. Jaffe, MD as a Venture Advisor on the firm’s healthcare investment team.
Dr. Jaffe will work closely with NEA’s medical device team out of the firm’s Menlo Park office.
He is an experienced venture capitalist with expertise in medical technology. As one of the founders and a Managing Director of Versant Ventures, a healthcare-focused venture capital firm, he has spent the past twenty years investing primarily in medical devices. Prior to founding Versant Ventures, Dr. Jaffe was a General Partner at Brentwood Venture Capital, where he led investments in medical device, drug delivery, biotechnology, healthcare services, and healthcare information system companies.
He has served on the boards of multiple medical technology companies, including Acclarent, St. Francis Medical Technologies, Therasense, Insulet, Novacept, and Ablation Frontiers, and is currently a Director of AlterG, Minerva Surgical, and DocMatter.
Dr. Jaffe has played an active role in the venture capital and medical device communities, including serving as a Director of the National Venture Capital Association (NVCA) and of the Western Association of Venture Capitalists. He currently serves as a Director of the Medical Device Innovation Consortium (MDIC), an FDA-industry collaboration focused on improving regulatory science.
New Enterprise Associates is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With more than $20 billion in cumulative committed capital since the firm’s first fund closed in 1978, NEA invests in technology and healthcare companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm’s track record of investing includes more than 225 portfolio company IPOs and more than 375 acquisitions.
FinSMEs
07/03/2019